GlassScriptPhysician profile
Timothy B White
NPI 1487602280
$1,920.46
in general payments reported to CMS, 2019-2025
16 companies · $615 in 2025
The $615 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $39.21 · 2021: $240 · 2022: $209 · 2023: $239 · 2024: $286 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.97 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $329.73 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $315.06 | 2021-2025 | Clareon, Tryptyr |
| Apellis Pharmaceuticals, INC. | $244.79 | 2023-2024 | Syfovre |
| Sun Pharmaceutical Industries INC. | $178.04 | 2021-2025 | |
| Optos, INC. | $173.29 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $148.71 | 2023-2024 | Miebo, Infuse, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $85.25 | 2022-2023 | |
| Allergan, INC. | $71.64 | 2021-2022 | |
| Harrow Eye, LLC | $62.97 | 2025 | Vevye |
| Dompe US, INC. | $57.19 | 2025 | Oxervate |
| Abbvie INC. | $30.50 | 2024 | |
| Rxsight INC | $23.96 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $23.32 | 2025 | Tyrvaya |
| Pfizer INC. | $17.68 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.